Fortitude Family Office’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13K Sell
193
-12
-6% -$799 ﹤0.01% 677
2026
Q1
$12.9K Buy
205
+135
+193% +$9.4K ﹤0.01% 566
2025
Q4
$4.65K Buy
70
+24
+52% +$1.55K ﹤0.01% 839
2025
Q3
$3.1K Sell
46
-91
-66% -$7.2K ﹤0.01% 1016
2025
Q2
$12K Buy
137
+41
+43% +$3.21K ﹤0.01% 499
2025
Q1
$6.56K Hold
96
﹤0.01% 655
2024
Q4
$7.47K Hold
96
﹤0.01% 716
2024
Q3
$6.44K Sell
96
-22
-19% -$1.81K ﹤0.01% 701
2024
Q2
$13.4K Hold
118
0.01% 361
2024
Q1
$16.4K Hold
118
0.01% 311
2023
Q4
$14.6K Buy
+118
New +$12.1K 0.01% 350

Other funds holding DXCM

Fortitude Family Office's DXCM Position: Q2 2026 in Review

Fortitude Family Office reduced its DexCom (DXCM) stake by 5.9% in Q2 2026, selling an estimated $799 and leaving 193 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #677.

Fortitude Family Office first reported a position in DXCM in Q4 2023 and has held it in 11 quarters since. The position peaked at $16.4K in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Fortitude Family Office held 193 shares of DexCom worth $13K as of Q2 2026.
  • Fortitude Family Office sold 12 DexCom shares in Q2 2026, an estimated $799.
  • DexCom made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #677 holding.
  • Fortitude Family Office first reported a position in DexCom in Q4 2023 and has held it in 11 quarters since.
  • Fortitude Family Office's DexCom position peaked at $16.4K in Q1 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.